TEDA BIOMEDICAL (08189) announced that Executive Director Mr. Xia Ruizhe has requested to transition from his executive position to a non-executive director role. The change is due to regulatory constraints associated with his holding of a Type 9 Asset Manager RO license issued by Hong Kong's Securities and Futures Commission.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.